Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial

International Journal of Cancer

Volumn 132, Issue 7, 2013, Pages 1547-1555

  Tran, Ben ^a   Brown, Andrew M K ^b   Bedard, Philippe L ^a   Winquist, Eric ^c   Goss, Glenwood D ^d   Hotte, Sebastien J ^e   Welch, Stephen A ^c   Hirte, Hal W ^e   Zhang, Tong ^a   Stein, Lincoln D ^b,f   Ferretti, Vincent ^b   Watt, Stuart ^b   Jiao, Wei ^b,f   Ng, Karen ^b   Ghai, Sangeet ^a   Shaw, Patricia ^a   Petrocelli, Teresa ^b   Hudson, Thomas J ^b,f   Neel, Benjamin G ^a,f,g   Onetto, Nicole ^b   Siu, Lillian L ^a   McPherson, John D ^b,f   Kamel Reid, Suzanne ^a,b,f   Dancey, Janet E ^b,h   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h QUEEN S UNIVERSITY   (Canada)

Author keywords

cancer genomes; molecular profiling; next generation sequencing; personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDARINIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GAMMA SECRETASE INHIBITOR; IRINOTECAN; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NAVELBINE; NOTCH INHIBITOR; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SORAFENIB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANALYZER; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CENTER; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG RESPONSE; EXON; FEASIBILITY STUDY; FEMALE; GENE SEQUENCE; GENETIC LINKAGE; GENOMICS; GENOTYPING TECHNIQUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; MUTATIONAL ANALYSIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; THYROID CANCER; TUMOR BIOPSY; TUMOR GENE; VALIDATION PROCESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GENES, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84873093569     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27817     Document Type: Article

References (28)

1. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010; 464: 993-8.
2. Arcila M, Lau C, Nafa K, Ladanyi M,. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011; 13: 64-73.
3. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011; 13: 504-13.
4. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
5. Lovly CM, Dahlman KB, Fohn LE, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012; 7: e35309.
6. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009; 4: e7887.
7. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
8. von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 33: 4877-83.
9. Desai AN, Jere A,. Next generation sequencing: ready for the clinics? Clin Genet 2012; 6: 503-10.
10. Zhao J, Grant SF,. Advances in whole genome sequencing technology. Curr Pharm Biotechnol 2011; 12: 293-305.
11. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra121.
12. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
13. Dancey JE, Bedard PL, Onetto N, Hudson TJ,. The genetic basis for cancer treatment decisions. Cell 2012; 148: 409-20.
14. Metzker ML,. Sequencing technologies-the next generation. Nat Rev Genet 2010; 11: 31-46.
15. Schilsky RL,. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010; 9: 363-6.
16. Tran B, Dancey JE, Kamel-Reid S, et al. Cancer genomics: technology, discovery, and translation. J Clin Oncol 2012; 30: 647-60.
17. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-50.
18. Rajasekaran R, Sethumadhavan R,. In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs. Appl Biochem Biotechnol 2010; 160: 1723-33.
19. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
20. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4.
21. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-13.
22. Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104: 1372-6.
23. Kalinsky K, Heguy A, Bhanot UK, et al. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 2011; 129: 635-43.
24. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-6.
25. Park JH, Han SW, Oh DY, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011; 68: 1045-55.
26. Bouchahda M, Karaboue A, Saffroy R, et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010; 66: 605-9.
27. Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: The M.D. Anderson Cancer Center Initiative. J Clin Oncol 2012 Sep 10. [Epub ahead of print]
28. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-82.